Gregor Poglajen1, Matjaz Sever1, Marko Cukjati1, Peter Cernelc1, Ivan Knezevic1, Gregor Zemljic1, François Haddad1, Joseph C Wu1, Bojan Vrtovec2. 1. From the Department of Cardiology, Advanced Heart Failure and Transplantation Center (G.P., G.Z., B.V.), Department of Hematology (M.S., P.C.), and Department of Cardiovascular Surgery (I.K.), University Medical Center Ljubljana, Ljubljana, Slovenia; National Blood Transfusion Institute, Ljubljana, Slovenia (M.C.); and Stanford Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA (F.H., J.C.W., B.V.). 2. From the Department of Cardiology, Advanced Heart Failure and Transplantation Center (G.P., G.Z., B.V.), Department of Hematology (M.S., P.C.), and Department of Cardiovascular Surgery (I.K.), University Medical Center Ljubljana, Ljubljana, Slovenia; National Blood Transfusion Institute, Ljubljana, Slovenia (M.C.); and Stanford Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA (F.H., J.C.W., B.V.). bvrtovec@stanford.edu.
Abstract
BACKGROUND: We investigated the effects of transendocardial CD34(+) cell transplantation in patients with ischemic cardiomyopathy. METHODS AND RESULTS: In a prospective crossover study, we enrolled 33 patients with ischemic cardiomyopathy with New York Heart Association class III and left ventricular ejection fraction <40%. In phase 1, patients were treated with medical therapy for 6 months. Thereafter, all patients underwent transendocardial CD34(+) cell transplantation. Peripheral blood CD34(+) cells were mobilized by granulocyte colony stimulating factor, collected via apheresis, and injected transendocardially in the areas of hibernating myocardium. Patients were followed up for 6 months after the procedure (phase 2). Two patients died during phase 1 and none during phase 2. The remaining 31 patients were 85% men, aged 57±6 years. In phase 1, we found no change in left ventricular ejection fraction (from 25.2±6.2% to 27.1±6.6%; P=0.23), N-terminal pro B-type natriuretic peptide (from 3322±3411 to 3672±5165 pg/mL; P=0.75) or 6-minute walk distance (from 373±68 to 411±116 m; P=0.17). In contrast, in phase 2 there was an improvement in left ventricular ejection fraction (from 27.1±6.6% to 34.9±10.9%; P=0.001), increase in 6-minute walk distance (from 411±116 to 496±113 m; P=0.001), and a decrease in N-terminal pro B-type natriuretic peptide (from 3672±5165 to 1488±1847 pg/mL; P=0.04). The average number of injected CD34(+) cells was 90.6±7.5×10(6). Higher doses of CD34(+) cells and a more diffuse distribution of transendocardial cell injections were associated with better clinical response. CONCLUSIONS: Transendocardial CD34(+) cell transplantation may be associated with improved left ventricular function, decreased N-terminal pro B-type natriuretic peptide levels, and better exercise capacity in patients with ischemic cardiomyopathy. These effects seem to be particularly pronounced in patients receiving diffusely distributed cell injections and high-dose cell therapy. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01350310.
BACKGROUND: We investigated the effects of transendocardial CD34(+) cell transplantation in patients with ischemic cardiomyopathy. METHODS AND RESULTS: In a prospective crossover study, we enrolled 33 patients with ischemic cardiomyopathy with New York Heart Association class III and left ventricular ejection fraction <40%. In phase 1, patients were treated with medical therapy for 6 months. Thereafter, all patients underwent transendocardial CD34(+) cell transplantation. Peripheral blood CD34(+) cells were mobilized by granulocyte colony stimulating factor, collected via apheresis, and injected transendocardially in the areas of hibernating myocardium. Patients were followed up for 6 months after the procedure (phase 2). Two patients died during phase 1 and none during phase 2. The remaining 31 patients were 85% men, aged 57±6 years. In phase 1, we found no change in left ventricular ejection fraction (from 25.2±6.2% to 27.1±6.6%; P=0.23), N-terminal pro B-type natriuretic peptide (from 3322±3411 to 3672±5165 pg/mL; P=0.75) or 6-minute walk distance (from 373±68 to 411±116 m; P=0.17). In contrast, in phase 2 there was an improvement in left ventricular ejection fraction (from 27.1±6.6% to 34.9±10.9%; P=0.001), increase in 6-minute walk distance (from 411±116 to 496±113 m; P=0.001), and a decrease in N-terminal pro B-type natriuretic peptide (from 3672±5165 to 1488±1847 pg/mL; P=0.04). The average number of injected CD34(+) cells was 90.6±7.5×10(6). Higher doses of CD34(+) cells and a more diffuse distribution of transendocardial cell injections were associated with better clinical response. CONCLUSIONS: Transendocardial CD34(+) cell transplantation may be associated with improved left ventricular function, decreased N-terminal pro B-type natriuretic peptide levels, and better exercise capacity in patients with ischemic cardiomyopathy. These effects seem to be particularly pronounced in patients receiving diffusely distributed cell injections and high-dose cell therapy. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01350310.
Authors: Vincenzo Grimaldi; Alberto Zullo; Francesco Donatelli; Francesco Paolo Mancini; Francesco Cacciatore; Claudio Napoli Journal: J Thorac Dis Date: 2018-07 Impact factor: 2.895
Authors: Arshed A Quyyumi; Alejandro Vasquez; Dean J Kereiakes; Marc Klapholz; Gary L Schaer; Ahmed Abdel-Latif; Stephen Frohwein; Timothy D Henry; Richard A Schatz; Nabil Dib; Catalin Toma; Charles J Davidson; Gregory W Barsness; David M Shavelle; Martin Cohen; Joseph Poole; Thomas Moss; Pamela Hyde; Anna Maria Kanakaraj; Vitaly Druker; Amy Chung; Candice Junge; Robert A Preti; Robin L Smith; David J Mazzo; Andrew Pecora; Douglas W Losordo Journal: Circ Res Date: 2016-11-07 Impact factor: 17.367
Authors: Bryon A Tompkins; Angela C Rieger; Victoria Florea; Monisha N Banerjee; Joshua M Hare Journal: Eur J Heart Fail Date: 2017-09-25 Impact factor: 15.534
Authors: Marko Banovic; Zlatibor Loncar; Atta Behfar; Marc Vanderheyden; Branko Beleslin; Andreas Zeiher; Marco Metra; Andre Terzic; Jozef Bartunek Journal: Stem Cell Res Ther Date: 2015-08-29 Impact factor: 6.832
Authors: Victoria Florea; Angela C Rieger; Darcy L DiFede; Jill El-Khorazaty; Makoto Natsumeda; Monisha N Banerjee; Bryon A Tompkins; Aisha Khan; Ivonne H Schulman; Ana Marie Landin; Muzammil Mushtaq; Samuel Golpanian; Maureen H Lowery; John J Byrnes; Robert C Hendel; Mauricio G Cohen; Krystalenia Valasaki; Marietsy V Pujol; Eduard Ghersin; Roberto Miki; Cindy Delgado; Fouad Abuzeid; Mayra Vidro-Casiano; Russell G Saltzman; Daniel DaFonseca; Lina V Caceres; Kevin N Ramdas; Adam Mendizabal; Alan W Heldman; Raul D Mitrani; Joshua M Hare Journal: Circ Res Date: 2017-09-18 Impact factor: 17.367